DelveInsight’s Glaucoma Market Insights report provides a thorough understanding of current treatment practices, emerging Glaucoma market share of the individual therapies, current and forecasted Glaucoma Market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Glaucoma is a disease that damages the eye’s optic nerve. It usually happens when fluid builds up in the front part of the eye. That extra fluid increases the pressure in eye, damaging the optic nerve. The condition is a leading cause of blindness for people over 60 years old. But blindness from glaucoma can often be prevented with early treatment.
Some of the key highlights of the Glaucoma market report
As per DelveInsight’s analysis, a higher percentage of diagnosed prevalence was observed for females, in comparison to males, in all the 7MM countries.
The total Glaucoma diagnosed prevalent population in the 7MM was estimated as 10,104,188 cases in 2020, which is expected to increase in the forecast period (2021-2030).
The Glaucoma Market Size of the 7MM was found to be USD 3,796 million in 2020.
The Glaucoma market companies are included like Aerie Pharmaceuticals, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical/Ube Industries, Bausch and Lomb, D.Western Therapeutics Institute (DWTI)/Kowa LTD., Alcon Research, Merck Sharp & Dohme Corp., Novartis/Alcon Research, Allergan, Senju Pharmaceuticals, and many others.
The Glaucoma market drugs are included like Rocklatan, Rhopressa, Xelpros (latanoprost ophthalmic emulsion) 0.005%, Eybelis Ophthalmic Solution 0.002% (DE-117, Omidenepag isopropyl), Vyzulta, Tapcom/DE-111 (Tafluprost/timolol maleate), Glanatec, Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%, Zioptan (tafluprost), DuoTrav PQ (travoprost/timolol), Travatan Z (travoprost ophthalmic solution) 0.004%, Lumigan 0.01% (bimatoprost ophthalmic solution), Durysta (Bimatoprost SR), AILAMIDE, Aibeta, and many others.
Get Access to a Free Copy of Our Latest Sample Report @ https://www.delveinsight.com/sample-request/glaucoma-market
Although glaucoma is not a curable disease, early diagnosis and adequate treatment are effective in reducing or preventing further optic nerve (ON) damage. The difficulty of distinguishing between eyes without glaucoma and eyes with early or subtle glaucoma is widely acknowledged. Furthermore, there is no unanimous opinion on what constitutes the first signs of damage in glaucoma.
There is no cure for glaucoma, but early treatment can often stop the damage and protect the vision. Doctors use a few different types of treatment for glaucoma, including medicines (usually eye drops), laser treatment, and surgery.
Glaucoma Risk Factors
There are several risk factors like age >60 years, genetic predisposition, certain eye characteristics (such as a pupillary defect, thin cornea, myopia), low educational status, smoking, African descent, and visual problems are associated with this indication and treatment pattern varies accordingly.
There are two major types of glaucoma, i.e., Primary open-angle glaucoma (POAG), and Angle-closure /glaucoma closed-angle glaucoma/narrow-angle glaucoma. The “angle” in both cases refers to the drainage angle inside the eye that controls the outflow of the watery fluid (aqueous) which is being produced inside the eye.
Glaucoma Market Drivers
Rich emerging pipeline
Development of treatment methods to tackle the situation of non-adherence
Development of advanced antiglaucoma medications
Patients-friendly dosage regimes
Rise in awareness
Glaucoma Market Barriers
Approaches to clinical practice
Lack of patient pool due to underdiagnosis
PDP-716: Sun Pharma Advanced Research Company Limited (SPARC)
PRO-122: Laboratorios Sophia S.A de C.V.
Glaucoma Market Report Scope
The report covers the descriptive overview of Glaucoma, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
Comprehensive insight has been provided into the Glaucoma epidemiology and treatment.
Additionally, an all-inclusive account of both the current and emerging therapies for Glaucoma is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
A detailed review of the Glaucoma market; historical and forecasted is included in the report, covering the 7MM drug outreach.
The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Glaucoma market
Glaucoma Market Companies
Sun Pharma Advanced Research Company Limited
Santen Pharmaceutical/Ube Industries, Bausch and Lomb
Western Therapeutics Institute (DWTI)/Kowa LTD.
Merck Sharp & Dohme Corp
And many others
Xelpros (latanoprost ophthalmic emulsion) 0.005%
Eybelis Ophthalmic Solution 0.002% (DE-117
Vyzulta, Tapcom/DE-111 (Tafluprost/timolol maleate)
Simbrinza (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%
DuoTrav PQ (travoprost/timolol)
Travatan Z (travoprost ophthalmic solution) 0.004%
Lumigan 0.01% (bimatoprost ophthalmic solution)
Durysta (Bimatoprost SR)
And many others
View Detailed Research Report Here @ https://www.delveinsight.com/sample-request/glaucoma-market
Table of content
Overview at a Glance
Executive Summary of Glaucoma
Disease Background and Overview
Treatment Algorithm for Open-Angle Glaucoma
Treatment for Glaucoma
Epidemiology and Patient Population
Organizations contributing towards Open-Angle Glaucoma (OAG)
Glaucoma: Seven Major Market Analysis
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States